National Bleeding Disorders Foundation/X
Aug 31, 2025, 09:45
Slow Uptake of Hemophilia Gene Therapies: Challenges in Access and Adoption
National Bleeding Disorders Foundation (NBDF) shared on X:
”A new forum piece in Research and Practice in Thrombosis and Haemostasis explores the complex factors at play, from long-term efficacy and safety questions to cost, access, and patient decision-making.
Read the full open-access article.”
A recent RPTH forum article examines why the uptake of hemophilia gene therapy remains modest, citing concerns over long-term efficacy and safety, high costs, access barriers, and competition from effective non-factor therapies.
Latest news in the field of bleeding disorders featured in Hemostasis Today.
-
May 12, 2026, 11:13Matteo Foschi: Grateful To Be Selected for The WSO Future Stroke Leaders Programme
-
May 12, 2026, 11:05Omid Seidizadeh: Strategies to Guide The 2nd 100 years of VWD Care and Research
-
May 12, 2026, 11:01Kate Scrivener: The Big Picture of Exercise Trials to Prevent Falls After Stroke
-
May 12, 2026, 10:39Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
-
May 12, 2026, 10:26Fabrice Cognasse: The EFS Is First and Foremost Part of a Medical Discipline – Transfusion
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC